Clene Inc. (NASDAQ: CLNN) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on neurodegenerative disease, has innovated a novel nanotherapeutics platform to create a new class of drugs—bioenergetic nanocatalysts. Clene’s lead drug candidate, CNM-Au8, is a the concentrated nanocrystalline gold (Au) suspension that drives critical cellular bioenergetic reactions in the CNS. CNM-Au8 increases cellular energy to accelerate neurorepair and improve neuroprotection. Currently, CNM-Au8 is being investigated for efficacy…